<DOC>
	<DOC>NCT00917839</DOC>
	<brief_summary>This study is designed to evaluate the neuroprotective effect of lamotrigine in the combination of interferon beta 1a once weekly intramuscular in patients with relapsing-remitting multiple sclerosis.</brief_summary>
	<brief_title>The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<criteria>definitive multiple sclerosis according to Mc Donald criteria clinical isolated syndrome according to Mc Donald criteria Expanded Disability Status Scale Score 05 Pretreatment with interferon beta 1a (Avonex) since at least 2 months before inclusion relapse within 30 days prior to randomisation steroid pulse therapy within 30 days prior to randomisation pregnancy or poor contraception contraindication for lamotrigine depressive symptoms drugs with possible interaction with lamotrigine according to instruction leaflet other medical relevant conditions but multiple sclerosis clinically relevant laboratory results contraindication for MRI missing informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>neuroprotection</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>brain atrophy</keyword>
	<keyword>mr-spectroscopy</keyword>
</DOC>